Research records indexed for Bremelanotide
This page carries 12 of the 96 records that the literature query returned for Bremelanotide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 84 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Bremelanotide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling pmid:42485063 | 2026 | Research Support, Non-U.S. Gov't | other | Not stated | Indexed as research support, non-u.s. gov't. study model from assigned MeSH headings do not state a study model. subject headings: Alpha-MSH; Chromatography, Liquid; Chromatography, High Pressure Liquid; Drug Stability; Computer Simulation. |
| Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder pmid:39793696 | 2025 | research-article, Research Support, N.I.H., Extramural | other | Not stated | Indexed as research-article, research support, n.i.h., extramural. study model from MeSH "Animals" with no rodent species heading. subject headings: Ventral Tegmental Area; Nucleus Accumbens; Mesocricetus; Peptides, Cyclic; Alpha-MSH. |
| Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells <i>via</i> Suppression of Survivin Expression pmid:39197897 | 2024 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Cell Line, Tumor; Glioblastoma; Brain Neoplasms; Alpha-MSH; Receptors, Melanocortin. |
| Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder pmid:36809187 | 2024 | Research Support, Non-U.S. Gov't, Review | other | Not stated | Indexed as research support, non-u.s. gov't, review. study model from MeSH "Humans" with no interventional publication type. subject headings: Peptides, Cyclic; Alpha-MSH; Sexual Dysfunctions, Psychological; Clinical Trials, Phase III As Topic. |
| An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder pmid:36242769 | 2023 | Review | other | Not stated | Indexed as review. study model from MeSH "Humans" with no interventional publication type. subject headings: Peptides, Cyclic; Alpha-MSH; Libido; Sexual Dysfunctions, Psychological. |
| The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women pmid:33455598 | 2022 | Research Support, Non-U.S. Gov't, Review | other | Not stated | Indexed as research support, non-u.s. gov't, review. study model from MeSH "Animals" with no rodent species heading. subject headings: Dopamine; Serotonin; Peptides, Cyclic; Alpha-MSH; Neurotransmitter Agents. |
| Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials pmid:35170192 | 2022 | research-article | other | Not stated | Indexed as research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Body Weight; Peptides, Cyclic; Alpha-MSH; Randomized Controlled Trials As Topic. |
| Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide pmid:35230162 | 2022 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Peptides, Cyclic; Alpha-MSH; Libido; Sexual Dysfunctions, Psychological. |
| Safety Profile of Bremelanotide Across the Clinical Development Program pmid:35147466 | 2022 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Peptides, Cyclic; Alpha-MSH; Blood Pressure Monitoring, Ambulatory; Libido. |
| The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results pmid:33538638 | 2021 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Peptides, Cyclic; Alpha-MSH; Libido; Sexual Dysfunctions, Psychological; Quality Of Life. |
| Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women pmid:33678061 | 2021 | Meta-Analysis | other | Not stated | Indexed as meta-analysis. study model from MeSH "Humans" with no interventional publication type. subject headings: Peptides, Cyclic; Alpha-MSH; Libido; Sexual Dysfunctions, Psychological. |
| Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent pmid:34642243 | 2021 | Review | other | Not stated | Indexed as review. study model from MeSH "Humans" with no interventional publication type. subject headings: Benzimidazoles; Peptides, Cyclic; Alpha-MSH; Libido. |
Where this page sits
Compound page: Bremelanotide. Class: Melanocortin receptor peptides.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 9941379, Bremelanotide. PubChem, National Library of Medicine (2026). pubchem:9941379
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA210557. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:bremelanotide
- Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med (2007). pmid:17958619
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med (2006). pmid:16839319
- Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) (2016). pmid:27181790
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol (2019). pmid:31599840
- Bremelanotide: First Approval. Drugs (2019). pmid:31429064
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.